ClinicalTrials.gg
CompletedNCT06528457PROTECTUpdated Oct 24, 2025

Study to Examine the Effects of Oral Fenretinide

A Phase 2 interventional study of ISLA101 and Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) in Dengue, sponsored by Island Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Island Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Dengue with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Dengue · United States.

Enrollment
55th of 65
15 · median 48
Started
2024
the only one that year
Phase 2
11 of 69
none open now
Registered
64th of 69
by date

Among the 69 studies in Dengue with a site in United States, this one is the 55th largest by enrollment of the 65 interventional ones that give a count, is the only one that started in 2024, is one of 11 in phase 2, and was the 64th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

4 of the 69 studies in Dengue with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Dengue with a site in United States, or all of them as a file.
02

Study summary

This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and symptoms of dengue virus (DENV) infection over 29 days following subcutaneous challenge of healthy subjects with 'Dengue 1 Live Virus Human Challenge' (DENV-1-LVHC). Humoral and cellular immune responses, both innate and adaptive, circulating virus, and changes in clinical laboratory measures will also be examined.

Read the detailed description

Pharmacology studies have identified the potential for fenretinide to inhibit the binding of the DENV nonstructural protein 5 (NS5) to host nuclear importins (IMPs) IMP-α and IMP-β1, thereby impairing infection and replication. This Phase 2 study is to evaluate the effectiveness of fenretinide in an encapsulated oral formulation (ISLA101) against challenge with Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) product, both prophylactically and therapeutically. Oral doses will be taken with a high fat meal to improve absorption, as fenretinide is known to have poor gut permeability attributed to its accumulation in lipophilic cell membranes.

03

Conditions studied

  • Dengue

Browse trials for

Keywords

  • dengue
  • Dengue with Warning Signs
  • Dengue Without Warning Signs
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects not of who are 18 years to 55 years of age (inclusive) at the time of consent
  • Females not of childbearing potential as defined in the following criteria:

    1. History of hysterectomy
    2. :

    i. Natural post-menopausal females with at least 12 months from natural spontaneous amenorrhea and a serum follicle-stimulating hormone (FSH) concentration ≥ 40 IU/L ii. Post-surgical females must have undergone bilateral oophorectomy at least 6 weeks prior to study

  • Male subjects with female partners of childbearing potential must agree to practice abstinence or use a combination of 2 of the following acceptable methods during the study and for at least 90 days after dosing:

    1. Partners with an intrauterine device (IUD) in place for at least 3 months
    2. Barrier method (condom or diaphragm) for at least 14 days prior to screening
    3. Partners using stable hormonal contraceptive for at least 3 months prior to the study
    4. History of vasectomy at least 3 months prior to signing the Form
  • Ability and willingness to sign informed consent
  • Passing score on comprehension test of at least 75%, with up to 3 attempts
  • Available for the study period
  • Provide consent for release of medical records from primary care physician, college or university, urgent care or emergency room visit

Exclusion criteria

Exclusion Criteria:

  • Known or suspected pregnancy (confirmed via a positive serum human chorionic gonadotropin (hCG) pregnancy test at screening), planned pregnancy during the study period, nursing, or lactation
  • Men who intend to father a child or donate sperm during the study period, and for 90 days after dosing with study drug
  • Any disorders of coagulation
  • Any current other than non-melanoma skin cancer
  • Men who intend to father a child during the study period (approximately 120 days)
  • Blood tests confirming infection with - 1 (HIV-1), , (assessed by HBsAg) virus, or suspicion of active influenza virus infection
  • Positive antibodies to dengue virus
  • Any history of dengue infection or dengue vaccination (licensed or experimental); or planned dengue vaccination during the study period
  • Recent (in the past 4 weeks) travel to any dengue endemic area or travel to a country with risk of Yellow Fever or Japanese encephalitis transmission
  • Positive urine screen for cocaine, amphetamines, opiates or methadone
  • Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
  • Active diabetes, active peptic ulcer disease (PUD), (COPD), coronary artery disease (CAD)
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Use of drugs listed in §6.6 that inhibit or induce Cytochrome P450 3A4 (CYP 3A4) enzymes within 30 days prior to administration of study drug and for the duration of Subject participation
  • Current, or a history of, auto-immune disease other than well controlled Hashimoto's thyroiditis
  • History of Guillain-Barré syndrome
  • Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the Subject from participating in the study
  • Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous vaccination or an allergy to specific medications/animals for which antigens may be in the virus preparations to include: shellfish allergy, fetal bovine serum, L-glutamine, neomycin and streptomycin
  • Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
  • Planning to donate blood in the 1 year following inoculation with dengue
  • Recent blood donation within prior 14 days of inoculation
  • Receipt of blood products or antibodies within 56 days of inoculation or during the study period
  • Planned travel during the study period (\~120 days) which would interfere with the ability to complete all study visits
  • Any laboratory abnormalities prior to inoculation for the tests specified in the protocol, that are considered by the investigator to be except those listed in exclusion criteria #25
  • subjects with the following grade 2 or greater lab abnormalities: Creatinine; Liver Function Tests - (ALT), aspartate aminotransferase (AST); (females and males); white blood count (WBC) decrease; decreased; (PT); partial thromboplastin time (PTT); Fibrinogen decrease
  • Significant screening physical examination abnormalities at the discretion of the investigator
  • Participation (active or follow-up phase) or planned participation in another vaccine, drug, medical device, or medical procedure clinical trial in the 4 weeks prior to this trial or during the trial.
  • Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation
  • Beliefs that restrict the administration of blood products or transfusions
  • Chronic medical condition that, in the opinion of the investigator, impacts Subject safety
  • Physician discretion
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cohort A

    The first cohort (Cohort A) allows examination of prophylaxis as well as treatment, as ISLA101 will be taken prior to inoculation and for 21 days thereafter. Subjects will be randomized 3:1 (active:control), enrolling in a single group three days prior to inoculation. Following the morning dose on the 4th day of dosing, all subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL).

    Drug: ISLA101 · Drug: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)

  • Placebo comparator
    Cohort B

    The first cohort (Cohort B) allows examination of prophylaxis as well as treatment, as placebo will be taken prior to inoculation and for 21 days thereafter. Subjects will be randomized 3:1 (active:control), enrolling in a single group three days prior to inoculation. Following the morning dose on the 4th day of dosing, all subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL).

    Drug: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) · Other: Placebo

  • Experimental
    Cohort C

    The second cohort (Cohort C) is planned to enroll in two groups of five subjects each, using 4:1 randomization (active:control). All subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL) on Day 1. After the inoculation, subjects will be evaluated in the clinic daily through day 18 (eighteen consecutive daily clinic visits). Dosing with ISLA101 will commence on the morning of Day 8 and continue with a total of 28 doses taken twice daily through Day 21.

    Drug: ISLA101 · Drug: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)

  • Placebo comparator
    Cohort D

    The second cohort (Cohort D) is planned to enroll in two groups of five subjects each, using 4:1 randomization (active:control). All subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL) on Day 1. After the inoculation, subjects will be evaluated in the clinic daily through day 18 (eighteen consecutive daily clinic visits). Dosing with placebo will commence on the morning of Day 8 and continue with a total of 28 doses taken twice daily through Day 21.

    Drug: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) · Other: Placebo

Interventions

  • ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).

    Also known as: fenretinide

  • DrugDengue 1 Live Virus Human Challenge (DENV-1-LVHC)

    The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.

  • OtherPlacebo

    Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).

06

What researchers measure

Primary outcomes

  1. Characterization of DENV viremia following inoculation

    Area under the curve of RNAemia by qRT-PCR for Cohort 1 Time to loss of detection of dengue virus RNAemia for Cohort 2

    Time frame: over 29 days from inoculation

Secondary outcomes

  1. To further characterize circulating virus in the two interventional groups versus control

    Time to positive RNAemia by qRT-PCR

    Time frame: over 29 days from inoculation

  2. To characterize circulating virus in the two interventional groups versus control

    Peak level of RNAemia by qRT-PCR

    Time frame: over 29 days from inoculation

  3. To characterize circulating virus in the two interventional groups versus control

    Duration of RNAemia by qRT-PCR (Cohort 1)

    Time frame: Over 29 days from inoculation

  4. To characterize circulating virus in the two interventional groups versus control

    Area under the curve of RNAemia by qRT-PCR (Cohort 2)

    Time frame: Over 29 days from inoculation

  5. To characterize circulating virus in the two interventional groups versus control

    Levels of infectious virus in blood by Plaque Assay

    Time frame: Over 29 days from inoculation

  6. To determine the effect of ISLA101 on solicited signs and symptoms of DENV when given prophylactically and through Day 21 post-inoculation, or only as delayed therapy

    The calculated score of solicited signs and symptoms associated with dengue virus infection, including any of the listed events below, will consist of summing the CTCAE grades across all days for all events, where the score will be summarized by number of positive subjects: * Fever, nausea, vomiting, fatigue, rash, abdominal pain, eye pain, bone pain, joint pain, muscle pain, headache.

    Time frame: Over 29 days from inoculation

  7. To compare the occurrence of unanticipated signs or symptoms of severe dengue

    The proportion of subjects with any of the following: * diffuse abdominal pain or tenderness, * persistent vomiting, * clinical fluid accumulation (ascites, pleural effusion), * mucosal bleeding, * lethargy, * restlessness, * liver enlargement \>2 cm, * increase in hematocrit concurrent with rapid decrease in platelet count. * severe plasma leakage, * severe hemorrhage, * severe organ impairment.

    Time frame: Over 29 days from inoculation

  8. To compare the need for hospital care between groups

    Proportion of subjects hospitalized for dengue symptoms

    Time frame: Over 29 days from inoculation

  9. To compare the need for hospital care between groups

    Length of hospitalization stay for dengue symptoms

    Time frame: Over 29 days from inoculation

  10. To compare the need for hospital care between groups

    Number of days in the intensive care unit for each hospitalization for dengue symptoms

    Time frame: Over 29 days from inoculation

  11. To evaluate changes from baseline in platelet among the three groups

    Number of participants with abnormal platelet counts, observed over 29 days from inoculation, will be summarized overall, by group, by duration and by toxicity grade for each group compared with control. A summary of subjects with shifts from baseline (relative to normal range) in laboratory test results will be provided.

    Time frame: Over 29 days from inoculation

  12. To describe the Cmax of ISLA101 at the tested dose, route, and duration

    Concentration-time plots of first and NEXT-TO-LAST dose of ISLA101

    Time frame: from first to next to last dose of ISLA101 (Day 24) for Cohort 1

  13. To describe the Tmax of ISLA101 at the tested dose, route, and duration

    Concentration-time plots of first and NEXT-TO-LAST dose of ISLA101

    Time frame: from first to next to last dose of ISLA101 (Day 24) for Cohort 1

  14. To describe the Cmax of ISLA101 at the tested dose, route, and duration

    Concentration-time plots of first and NEXT-TO-LAST dose of ISLA101

    Time frame: from first to next to last dose of ISLA101 (Day 21) for Cohort 2

  15. To describe the Tmax of ISLA101 at the tested dose, route, and duration

    Concentration-time plots of first and NEXT-TO-LAST dose of ISLA101

    Time frame: from first to next to last dose of ISLA101 (Day 21) for Cohort 2

07

Study locations

1 site
  • SUNY Upstate Medical University
    East Syracuse, New York 13057, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in May 2025, 8 months.

Of 21 industry-sponsored phase 2 interventional studies under Dengue, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 8 months is below that.

Counting every sponsor, half of 31 studies reached it within 20 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 30, 2024
StartActual
Sep 5, 2024
Primary completionActual
May 21, 2025
CompletionActual
Jul 21, 2025
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528457
Lead sponsor
Island Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Sep 5, 2024
Primary completion
May 21, 2025
Completion
Jul 21, 2025
Last update
Oct 24, 2025

Study contacts

Bert Slade, MD
study director · CCRS

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenretinide

Start the discussion